Global importance of new treatment strategies to efforts to control hepatitis B virus

References

• Nguyen MH, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33(2):e00046–19. doi:10.1128/CMR.00046-19
   PubMed Web of Science ®Google Scholar
• Zampino R, Boemio A, Sagnelli C, et al. Hepatitis B virus burden in developing countries world. J Gastroenterol. 2015;21(42):11941–11953. doi:10.3748/wjg.v21.i42.11941
   Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi:10.1016/j.jhep.2017.03.021.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: aASLD 2018 hepatitis B guidance. Clin Liver Dis. 2018;12(1):33–34. doi: 10.1002/cld.728.
   PubMedGoogle Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98. doi:10.1007/s12072-015-9675-4
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. France: World Heath Organization. 2015. p. 1–166.
   Google Scholar
• Lampertico P, Agarwal K, Berg T, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis B; 2021. [cited 2022 May 10]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-b
   Google Scholar
• The Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383–403.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Hepatitis Report 2017. France: World Health Organization. 2017.
   Google Scholar
• World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030. 2022.
   Google Scholar
• Khetsuriani N, Lesi O, Desai S, et al. Progress toward the elimination of mother-to-child transmission of hepatitis B virus — worldwide, 2016–2021. MMWR Morb Mortal Wkly Rep. 2022;71(30):958–963. doi:10.15585/mmwr.mm7130a2
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Chronic hepatitis B virus infection: developing drugs for treatment guidance for industry. US: U.S. Department of Health and Human ServicesFood and Drug Administration Center for Drug Evaluation and Research (CDER); 2022.
   Google Scholar
• Cornberg M, Lok AS, Terrault NA, et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger). J Hepatol. 2020;72(3):539–557. doi:10.1016/j.jhep.2019.11.003
   PubMed Web of Science ®Google Scholar
• Broquetas T, Carrion JA. Current perspectives on nucleos(t)ide analogue therapy for the long-term treatment of hepatitis B. Virus Hepat Med. 2022;14(87–100):87–100. doi:10.2147/HMER.S291976.
   PubMedGoogle Scholar
• Geng J, Bao H, Chen Y, et al. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther. 2020;18(8):823–834. doi:10.1080/14787210.2020.1760843
   PubMed Web of Science ®Google Scholar
• Sbarigia U, Vincken T, Wigfield P, et al. A comparative network meta-analysis of standard of care treatments in treatment-naive chronic hepatitis B patients. J Comp Eff Res. 2020;9(15):1051–1065. doi:10.2217/cer-2020-0068
   PubMed Web of Science ®Google Scholar
• de Fraga RS, Van VV, Mendes LCA, et al. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol. 2020;55(5):496–514. doi:10.1007/s00535-020-01680-0
   PubMed Web of Science ®Google Scholar
• de FRS, Van VV, Mendes LCA, et al. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol. 2020;55(5):496–514. doi:10.1007/s00535-020-01680-0
   PubMed Web of Science ®Google Scholar
• Yang YM, Choi EJ. Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection. Ther Clin Risk. Manag. 2017;13(1273–1285):1273–1285. doi:10.2147/TCRM.S143286.
   Google Scholar
• Chen MB, Wang H, Zheng QH, et al. Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B: a systematic review and meta-analysis. PLoS One. 2019;14(11):e0224773. doi:10.1371/journal.pone.0224773
   PubMed Web of Science ®Google Scholar
• Con D, Goodwin T, Majeed A, et al. Comparison of 48-week efficacy of tenofovir vs entecavir for patients with chronic hepatitis B: a network meta-analysis. J Viral Hepat. 2021;28(1):40–50. doi:10.1111/jvh.13400
   PubMed Web of Science ®Google Scholar
• Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196–206. doi:10.1016/S2468-1253(16)30107-8
   PubMed Web of Science ®Google Scholar
• Choi WM, Choi J, Lim YS. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients with Chronic HBV Infection: a Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021;19(2):246–258 e9. doi:10.1016/j.cgh.2020.05.008.
   PubMed Web of Science ®Google Scholar
• Tseng CH, Tseng CM, Wu JL, et al. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: a systematic review. J Gastroenterol Hepatol. 2020;35(10):1684–1693. doi:10.1111/jgh.15078
   PubMed Web of Science ®Google Scholar
• Tseng C-H, Hsu Y-C, Chen T-H, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(12):1039–1052. doi:10.1016/S2468-1253(20)30249-1
   PubMed Web of Science ®Google Scholar
• Yardeni D, Ghany MG. Review article: hepatitis B—current and emerging therapies. Aliment Pharmacol Ther. 2022;55(7):805–819. doi:10.1111/apt.16828.
   PubMed Web of Science ®Google Scholar
• Hutin Y, Nasrullah M, Easterbrook P, et al. Access to treatment for hepatitis B virus infection — worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2018;67(28):773–777. doi:10.15585/mmwr.mm6728a2.
   PubMed Web of Science ®Google Scholar
• Ogawa E, Yeo YH, Dang N, et al. Diagnosis rates of chronic hepatitis B in privately insured patients in the United States. JAMA Netw Open. 2020;3(4):e201844. doi:10.1001/jamanetworkopen.2020.1844
   PubMed Web of Science ®Google Scholar
• Preventive Services Task Force US, Krist AH, Davidson KW, et al. Screening for Hepatitis B Virus Infection in Adolescents and Adults: uS Preventive Services Task Force Recommendation Statement. JAMA. 2020;324(23):2415–2422. doi: 10.1001/jama.2020.22980.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Peer review plan for recommendations for hepatitis B screening and testing 2022 [updated 6 Apr 2022; cited 2022 5 Aug]. Available from: https://www.cdc.gov/hepatitis/policy/isireview/hepbscreeningandtesting.htm#:~:text=Universal%2C%20one%2Dtime%20hepatitis%20B,to%20screen%20for%20hepatitis%20B
   Google Scholar
• Cui F, Blach S, Manzengo Mingiedi C, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(4):332–342. doi:10.1016/S2468-1253(22)00386-7
   PubMed Web of Science ®Google Scholar
• Lin C, Clark R, Tu P, et al. The disconnect in hepatitis screening: participation rates, awareness of infection status, and treatment-seeking behavior. J Glob Health. 2019;9(1):010426–010426. doi: 10.7189/jogh.09.010426.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global health sector strategy on viral hepatitis 2016–2021: towards ending viral hepatitis. France: World Heath Organization. 2021.
   Google Scholar
• Freeland C, Farrell S, Kumar P, et al. Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. BMC Public Health. 2021;21(1):1004. doi:10.1186/s12889-021-11093-0
   PubMed Web of Science ®Google Scholar
• Wong RJ, Kaufman HW, Niles JK, et al. Simplifying Treatment Criteria in Chronic Hepatitis B: reducing Barriers to Elimination. Clin Infect Dis. 2023;76(3):e791–e800. doi:10.1093/cid/ciac385
   PubMedGoogle Scholar
• Jiang XY, Huang B, Huang DP, et al. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. World J Gastroenterol. 2021;27(11):1101–1116. doi:10.3748/wjg.v27.i11.1101
   PubMed Web of Science ®Google Scholar
• Huang DQ, Tran A, Yeh ML, et al. Antiviral therapy substantially reduces hepatocellular carcinoma risk in chronic Hepatitis B patients in the indeterminate phase. Hepatology. 2023;Publish Ahead of Print. doi:10.1097/HEP.0000000000000459.
   Google Scholar
• Tan M, Bhadoria AS, Cui F, et al. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(2):106–119. doi: 10.1016/S2468-1253(20)30307-1.
   PubMed Web of Science ®Google Scholar
• Zhou K, Wahed AS, Cooper S, et al. Phase transition is infrequent among North American adults with e-antigen-negative chronic hepatitis B and low-level viremia. Am J Gastroenterol. 2019;114(11):1753–1763. doi:10.14309/ajg.0000000000000400
   PubMed Web of Science ®Google Scholar
• Spradling PR, Xing J, Rupp LB, et al. Infrequent clinical assessment of chronic hepatitis B patients in United States general healthcare settings. Clin Infect Dis. 2016;63(9):1205–1208. doi:10.1093/cid/ciw516
   PubMed Web of Science ®Google Scholar
• Lee HW, Kim SU, Park JY, et al. Prognosis of untreated minimally active chronic hepatitis B patients in comparison with virological responders by antivirals. Clin Transl Gastroenterol. 2019;10(6):e00036. doi:10.14309/ctg.0000000000000036
   PubMedGoogle Scholar
• Yao K, Liu J, Wang J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat. 2021;28(7):1025–1033. doi:10.1111/jvh.13511
   PubMed Web of Science ®Google Scholar
• Lee JS, K BK, Park JY, et al. A nationwide prospective cohort study on chronic hepatitis B in Korea: an interim analysis. Hepatol. 2021;74:443A–444A.
   Web of Science ®Google Scholar
• Harris A, Iqbal K, Schillie S, et al. Increases in acute hepatitis B virus infections — Kentucky, Tennessee, and West Virginia, 2006–2013. MMWR Morb Mortal Wkly Rep. 2016;65(3):47–50. doi:10.15585/mmwr.mm6503a2
   PubMed Web of Science ®Google Scholar
• Ly KN, Xing J, Spradling PR. Trends in prevalence and characteristics of resolved and current hepatitis B among US-Born persons: national health and nutrition examination survey, 2001-2018. J Infect Dis. 2021;224(5):804–812. doi:10.1093/infdis/jiab224.
   PubMed Web of Science ®Google Scholar
• Kim GL, Han S, Choi J, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67(5):945–952. doi:10.1136/gutjnl-2017-314904.
   PubMed Web of Science ®Google Scholar
• Jeon MY, Kim BK, Lee JS, et al. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. B Clin Mol Hepatol. 2021;27(2):295–304. doi:10.3350/cmh.2020.0216
   PubMed Web of Science ®Google Scholar
• Wu W, Zhu Y, Yu C, et al. Clinical features of treatment-naive patients with hepatitis B virus infection. Medicine. 2017;96(16):e6660. doi:10.1097/MD.0000000000006660
   PubMed Web of Science ®Google Scholar
• Huang DQ, Li X, Le MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase. Clin Gastroenterol Hepatol. 2022;20(8):1803–1812 e5. doi: 10.1016/j.cgh.2021.01.019.
   PubMed Web of Science ®Google Scholar
• Teng W, Chang TT, Yang HI, et al. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. Hepatol Int. 2021;15(6):1421–1430. doi:10.1007/s12072-021-10263-x
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang F, Li L, et al. Expanding antiviral therapy indications for HBeAg-negative chronic hepatitis B patients with normal ALT and positive HBV DNA. Precis Clin Med. 2022;5(4):bac030. doi:10.1093/pcmedi/pbac030
   Google Scholar
• Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology. 2017;66(2):335–343. doi:10.1002/hep.28916
   PubMed Web of Science ®Google Scholar
• Lee J, Cho S, Kim HJ, et al. High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: a nationwide cohort study. J Viral Hepat. 2021;28(2):353–363. doi:10.1111/jvh.13418
   PubMed Web of Science ®Google Scholar
• Fu KY, Hsieh ML, Chen JA, et al. Association between medication adherence and disease outcomes in patients with hepatitis B-related cirrhosis: a population-based case-control study. BMJ Open. 2022;12(6):e059856. doi:10.1136/bmjopen-2021-059856
   PubMed Web of Science ®Google Scholar
• Ford N, Scourse R, Lemoine M, et al. Adherence to nucleos(t)ide analogue therapies for chronic hepatitis B infection: a systematic review and meta-analysis. Hepatol Commun. 2018;2(10):1160–1167. doi:10.1002/hep4.1247
   PubMed Web of Science ®Google Scholar
• Kao JH, Jeng WJ, Ning Q, et al. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int. 2021;15(4):833–851. doi:10.1007/s12072-021-10223-5
   PubMed Web of Science ®Google Scholar
• Hall S, Vogrin S, Wawryk O, et al. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut. 2022;71(8):1629–1641. doi:10.1136/gutjnl-2020-323979
   PubMed Web of Science ®Google Scholar
• Li G, Wang G, Hsu FC, et al. Effects of depression, anxiety, stigma, and disclosure on health-related quality of life among chronic hepatitis B patients in dalian. China Am J Trop Med Hyg. 2020;102(5):988–994. doi:10.4269/ajtmh.19-0007
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Younossi I, et al. Development and validation of a hepatitis B-specific health-related quality-of-life instrument: cLDQ-HBV. J Viral Hepat. 2021;28(3):484–492. doi:10.1111/jvh.13451
   PubMed Web of Science ®Google Scholar
• Xue X, Cai S, Ou H, et al. Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence. 2017;11(85–93):85–93. doi:10.2147/PPA.S127139
   PubMedGoogle Scholar
• Evon DM, Lin HS, Khalili M, et al. Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. Aliment Pharmacol Ther. 2020;51(4):457–468. doi: 10.1111/apt.15618.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Burak OA, Liou I, et al. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B. J Hepatol. 2020;70(1):24–32. doi: 10.1016/j.jhep.2018.09.021.
   Web of Science ®Google Scholar
• Campbell C, Wang T, McNaughton AL, et al. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat. 2021;28(3):493–507. doi:10.1111/jvh.13452
   PubMed Web of Science ®Google Scholar
• Kuang XJ, Jia RR, Huo RR, et al. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Viral Hepat. 2018;25(9):1026–1037. doi:10.1111/jvh.12905
   PubMed Web of Science ®Google Scholar
• Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016;36(9):1239–1251. doi:10.1111/liv.13142.
   PubMed Web of Science ®Google Scholar
• Tan Y, Wei S, Zhang W, et al. Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review. cancer Manag Res. 2019;11(705–713):705–713. doi:10.2147/CMAR.S188238
   PubMedGoogle Scholar
• Zhu L, Kong J, Zheng Y, et al. Development and initial validation of the chronic hepatitis B quality of life instrument (CHBQOL) among Chinese patients. Qual Life Res. 2019;28(11):3071–3081. doi:10.1007/s11136-019-02240-7
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Younossi I, et al. Long-term effects of treatment for chronic HBV infection on patient-reported outcomes. Clin Gastroenterol Hepatol. 2019;17(8):1641–1642.e1. doi:10.1016/j.cgh.2018.09.041
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Younossi I, et al. Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: the impact of hepatitis B and C viral replication. Liver Int. 2019;39(10):1837–1844. doi:10.1111/liv.14171
   PubMed Web of Science ®Google Scholar
• Lee H, Kim BK, Jang S, et al. Cost-effectiveness analysis of antiviral therapy for untreated minimally active chronic hepatitis B to prevent liver disease progression. Clin Transl Gastroenterol. 2021;12(2):e00299. doi:10.14309/ctg.0000000000000299
   PubMed Web of Science ®Google Scholar
• Chahal HS, Peters MG, Harris AM, et al. Cost-effectiveness of hepatitis B virus infection screening and treatment or vaccination in 6 high-risk populations in the United States. Open Forum Infect Dis. 2019;6(1):ofy353. doi:10.1093/ofid/ofy353
   PubMed Web of Science ®Google Scholar
• Nayagam S, Conteh L, Sicuri E, et al. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in the Gambia: an economic modelling analysis. Lancet Glob Health. 2016;4(8):e568–e578. doi:10.1016/S2214-109X(16)30101-2
   PubMed Web of Science ®Google Scholar
• Wright CM, Boudarène L, Ha NT, et al. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries BMC. BMC Public Health. 2018;18(1):373. doi:10.1186/s12889-018-5261-8
   PubMedGoogle Scholar